Skip to main content
. 2023 Apr 25;2023:1990259. doi: 10.1155/2023/1990259

Table 1.

Baseline characteristics of patients with giant prolactinoma prior to treatment.

Case no Age (years) Gender Race Presenting symptoms Initial PRL (μg/L) Preoperative central hormone deficit(s) Largest tumor dimension (cm) Initial tumor volume (cm3)
1 38 Male White Headache, weakness, visual deficit, behavior changes N/A–not evaluated N/A–not evaluated 5 40.0
2 53 Male White Weakness, visual deficit, ophthalmoplegia, behavior changes 3,482 Hypogonadism, hypothyroidism, adrenal insufficiency 7.7 109.3
3 20 Female Black Secondary amenorrhea, headache, visual deficit 1,111 Hypogonadism, hypothyroidism, adrenal insufficiency 6 27.3
4 39 Male Black Headache, weakness, visual deficit, ophthalmoplegia, behavior changes, low libido 2,498 Hypogonadism 4.6 22.8
5 26 Male White Headache, visual deficit, ophthalmoplegia, low libido 686 Hypogonadism 5.9 31.0
6 33 Male White Galactorrhea, headache, visual deficit, low libido >13,000 Hypogonadism 5 30.6
7 47 Male White Headache, ophthalmoplegia, behavior change, memory loss ∼100ǂ N/A–not evaluated 9 N/A–unavailable
8 51 Female Black Visual deficit, low libido 11,477 Hypogonadism 6 46.5

Growth hormone deficiency was not tested in any patient. Patient declined preoperative blood evaluation. ǂExact value unavailable, serial dilution was not performed, falsely low prolactin level was consistent with hook effect. Tumor volume calculated using geometric formula, volume = ½ (L × W × H). PRL (prolactin).